Shares of Retrophin Inc (NASDAQ:RTRX) shot up 5.6% during trading on Monday . The stock traded as high as $19.61 and last traded at $19.55. 330,350 shares traded hands during trading, a decline of 24% from the average session volume of 435,357 shares. The stock had previously closed at $18.51.

A number of research analysts have weighed in on RTRX shares. BofA Securities assumed coverage on shares of Retrophin in a research note on Monday, August 24th. They issued a “buy” rating and a $30.00 price target on the stock. Zacks Investment Research cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Thursday, August 6th. Canaccord Genuity reiterated a “buy” rating and set a $26.00 target price on shares of Retrophin in a report on Tuesday, May 19th. BidaskClub raised Retrophin from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, BTIG Research initiated coverage on Retrophin in a research report on Tuesday, June 16th. They set a “buy” rating and a $25.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $26.57.

The company has a debt-to-equity ratio of 0.66, a current ratio of 7.23 and a quick ratio of 7.14. The business’s 50-day moving average is $18.96 and its two-hundred day moving average is $16.90. The firm has a market cap of $993.69 million, a P/E ratio of -9.40 and a beta of 0.74.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.58) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.58). The company had revenue of $48.43 million during the quarter, compared to the consensus estimate of $48.50 million. Retrophin had a negative net margin of 49.13% and a negative return on equity of 36.38%. Equities research analysts predict that Retrophin Inc will post -1.65 EPS for the current year.

In other Retrophin news, Director Steve Aselage sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the director now directly owns 238,732 shares in the company, valued at $4,774,640. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 13,370 shares of company stock valued at $267,026 over the last three months. Insiders own 4.63% of the company’s stock.

A number of hedge funds have recently made changes to their positions in RTRX. Vanguard Group Inc. grew its position in shares of Retrophin by 15.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,970,844 shares of the biopharmaceutical company’s stock valued at $60,636,000 after acquiring an additional 396,250 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Retrophin by 14.1% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 684,246 shares of the biopharmaceutical company’s stock valued at $13,965,000 after purchasing an additional 84,355 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in Retrophin by 6.1% during the second quarter. Nuveen Asset Management LLC now owns 595,533 shares of the biopharmaceutical company’s stock worth $12,155,000 after purchasing an additional 34,000 shares during the period. Charles Schwab Investment Management Inc. increased its position in Retrophin by 16.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 403,354 shares of the biopharmaceutical company’s stock worth $8,233,000 after buying an additional 57,292 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Retrophin by 27.3% in the second quarter. Point72 Asset Management L.P. now owns 386,126 shares of the biopharmaceutical company’s stock valued at $7,881,000 after buying an additional 82,746 shares during the period.

About Retrophin (NASDAQ:RTRX)

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: What is meant by a buy rating?

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.